Seroprevalence of Epstein-Barr Virus, Cytomegalovirus, and Polyomaviruses in Children with Inflammatory Bowel Disease
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
Odkazy
PubMed
26091801
DOI
10.1007/s10620-015-3764-z
PII: 10.1007/s10620-015-3764-z
Knihovny.cz E-zdroje
- Klíčová slova
- Azathioprine, Cytomegalovirus, Epstein–Barr virus, Immunosuppressive therapy, Inflammatory bowel disease, Infliximab,
- MeSH
- azathioprin škodlivé účinky MeSH
- Crohnova nemoc diagnóza farmakoterapie epidemiologie imunologie MeSH
- cytomegalovirové infekce diagnóza epidemiologie imunologie virologie MeSH
- dítě MeSH
- hostitel s imunodeficiencí MeSH
- imunosupresiva škodlivé účinky MeSH
- infekce virem Epsteina-Barrové diagnóza epidemiologie imunologie virologie MeSH
- infliximab škodlivé účinky MeSH
- lidé MeSH
- logistické modely MeSH
- mladiství MeSH
- multivariační analýza MeSH
- odds ratio MeSH
- oportunní infekce diagnóza epidemiologie imunologie virologie MeSH
- polyomavirové infekce diagnóza epidemiologie imunologie virologie MeSH
- předškolní dítě MeSH
- prevalence MeSH
- průřezové studie MeSH
- rizikové faktory MeSH
- séroepidemiologické studie MeSH
- sérologické testy MeSH
- ulcerózní kolitida diagnóza farmakoterapie epidemiologie imunologie MeSH
- věkové faktory MeSH
- virová nálož MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- předškolní dítě MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Česká republika epidemiologie MeSH
- Názvy látek
- azathioprin MeSH
- imunosupresiva MeSH
- infliximab MeSH
BACKGROUND: Young age and thiopurine therapy are risk factors for lymphoproliferative disease among patients with inflammatory bowel disease (IBD). AIMS: The aims of this study were to evaluate the prevalence of seropositivity for the Epstein-Barr virus (EBV) and human cytomegalovirus (CMV) among children and adolescents with IBD, to assess the viral load of EBV, CMV, and BK and JC polyomaviruses (BKV, JCV) in these patients, and to assess the influence of different therapeutic regimens on seroprevalence and viral load. METHODS: Children who had been followed in our center were tested for EBV, CMV, BKV, and JCV in a cross-sectional study. One hundred and six children were included who had Crohn's disease (68%), ulcerative colitis (29%), and unclassified IBD (3%). RESULTS: We found that 64% of patients were EBV seropositive. The proportion of EBV seropositive patients increased during childhood. Azathioprine therapy (p = 0.003) was associated with EBV seropositivity in a multiple logistic regression model, after adjusting for gender, age, and disease activity at determination. We found a significant association between the number of polymerase chain reaction copies and infliximab dose (p = 0.023). We did not find any significant association between CMV serology and CMV, BKV, or JCV viral load, or any other therapeutic regimen or clinical characteristics. CONCLUSIONS: Treatment with azathioprine appears to be a risk factor for early EBV seropositivity in children with IBD, and the infliximab dose was associated with a higher EBV viral load.
